All In Biotech

Drug Trial Radar · NCT05102552

Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

A Single-Center, Randomized, Open-label, Multiple-Dose, Single-Sequence Crossover Study, Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 19, 2021

Primary completion

Mar 25, 2022

Study completion Aug 15, 2022

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, Open-Label, Multiple Dose study to evaluate the relative bioavailability of Treatment A, Treatment B, and Treatment C

Conditions

  • Healthy Volunteer

Interventions

  • SPN-817, Treatment BDrug

    SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

  • SPN-817, Treatment CDrug

    SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

  • BIS-001, Treatment ADrug

    BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative BioavailabilityTime frame: 22 days
  2. Relative BioavailabilityTime frame: 22 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.